Biostage (BSTG) Given Media Sentiment Rating of 0.17
Headlines about Biostage (NASDAQ:BSTG) have trended somewhat positive recently, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biostage earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.4338755166524 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s scoring:
- Primed for Breakout or Bust? A look at Biostage, Inc. (:BSTG) – FLBC News (flbcnews.com)
- Biostage Inc (BSTG) AO Seeing a Consistent Downtrend – FLBC News (flbcnews.com)
- Comparable Company Analysis: Biostage, Inc. (BSTG), Twilio Inc … – AllStockNews (allstocknews.com)
- Biostage, Inc. (BSTG) noted a price change of -1.35% and Meridian … – Stocks Gallery (stocksgallery.com)
- Going Through the Chart for Biostage, Inc. (BSTG) – Economic News (economicsandmoney.com)
Separately, Maxim Group reiterated a “hold” rating on shares of Biostage in a research report on Monday, August 14th.
Biostage (BSTG) traded down 3.8356% on Friday, hitting $0.3159. The stock had a trading volume of 1,874,116 shares. Biostage has a 12 month low of $0.22 and a 12 month high of $1.42. The company has a 50-day moving average of $0.45 and a 200 day moving average of $0.37. The company’s market cap is $12.30 million.
Biostage (NASDAQ:BSTG) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.03. On average, analysts predict that Biostage will post ($0.42) EPS for the current fiscal year.
In other Biostage news, insider Saverio Lafrancesca acquired 150,000 shares of the firm’s stock in a transaction dated Wednesday, August 23rd. The shares were acquired at an average price of $0.32 per share, for a total transaction of $48,000.00. Following the completion of the acquisition, the insider now directly owns 193,998 shares of the company’s stock, valued at $62,079.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.30% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Biostage (BSTG) Given Media Sentiment Rating of 0.17” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/08/27/biostage-bstg-given-media-sentiment-rating-of-0-17.html.
Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.
Receive News & Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.